Open-Label Expanded Access for Ebola-Infected Patients to Receive Human MAb Ansuvimab As Therapeutic or for HR PEP
Clinical trial NCT05067166 · AVAILABLE
Trial details
- NCT number
- NCT05067166
- Sponsor
- Ridgeback Biotherapeutics, LP
- Status
- AVAILABLE
- Study type
- EXPANDED_ACCESS
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.